RNA Targeting Small Molecule Drug Discovery Market Report 2026

The rna targeting small molecule drug discovery market size has grown exponentially in recent years. It will grow from $2.13 billion in 2025 to $2.6 billion in 2026 at a compound annual growth rate (CAGR) of 22.3%. The growth in the historic period can be attributed to limited druggability of protein targets, rising prevalence of genetic disorders, advances in rna biology research, growth in academic-industry collaborations, early success of rna-based therapeutics.

The rna targeting small molecule drug discovery market size is expected to see exponential growth in the next few years. It will grow to $6.04 billion in 2030 at a compound annual growth rate (CAGR) of 23.5%. The growth in the forecast period can be attributed to ai-enabled rna target identification, increasing investment in precision medicine, expansion of rna therapeutics pipelines, improved rna delivery technologies, regulatory support for novel modalities. Major trends in the forecast period include ai-driven rna structure prediction, expansion of rna-targeted oncology pipelines, advances in rna-specific small molecule libraries, improved rna binding selectivity and specificity, integration of multi-omics in rna drug discovery.

The rising incidence of cancer, genetic disorders, and viral infections is expected to support the expansion of the RNA-targeted small-molecule drug discovery market in the coming years. Cancer encompasses a range of diseases marked by uncontrolled cell growth within the body. Viral infections are caused by viruses, which are microscopic infectious agents that replicate only inside living cells. RNA-targeted drug discovery is applied in the treatment of cancer, genetic disorders, and viral infections because these conditions are associated with genetic abnormalities or dysfunctional genetic material, which can be addressed using drugs developed through RNA-targeting approaches. For example, in February 2024, according to a report released by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide in 2022. Lung cancer accounted for the highest number of cases at 2.5 million (12.4%), followed by female breast cancer with 2.3 million cases (11.6%), colorectal cancer with 1.9 million cases (9.6%), prostate cancer with 1.5 million cases (7.3%), and stomach cancer with 970,000 cases (4.9%). By 2050, the number of new cancer cases is projected to increase by 77%, exceeding 35 million annually. As a result, the growing prevalence of cancer, genetic disorders, and viral infections is driving the growth of the RNA-targeted small-molecule drug discovery market.

Key companies operating in the RNA-targeting small-molecule drug discovery market are introducing advanced solutions such as software-as-a-service platforms to strengthen their competitive position. Software-as-a-service (SaaS) is a delivery model in which software applications are hosted by external providers and accessed by users through the Internet. For instance, in December 2023, Merck & Co. Inc., a US-based science and technology company, launched AIDDISON. This platform recommends optimal methods for synthesizing selected drug candidates. Such an approach has the potential to significantly reduce costs associated with drug discovery and improve the likelihood of successfully bringing new therapies to patients. By connecting virtual molecular design with practical manufacturability, the platform enhances treatment delivery by uncovering valuable insights from large datasets. To accelerate drug development timelines, this AI-driven system combines computer-aided drug design, machine learning, and generative artificial intelligence.

In June 2025, Novartis AG, a Switzerland-based company specializing in pharmaceuticals, gene therapies, and innovative medicines, acquired Regulus Therapeutics Inc. for up to $1.7 billion. This acquisition is intended to reinforce Novartis’s renal disease pipeline by gaining access to Regulus’s lead microRNA inhibitor for autosomal dominant polycystic kidney disease (ADPKD) and advancing its capabilities in RNA-targeted drug discovery. Regulus Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on discovering and developing therapies that target microRNAs.

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation.

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rna targeting small molecule drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the rna targeting small molecule drug discovery market by increasing costs of imported laboratory instruments, specialized reagents, and high-throughput screening technologies used in early-stage research. these impacts are most pronounced across research use and therapeutic development segments, particularly in regions dependent on cross-border biotech supply chains such as asia-pacific and europe. oncology and genetic disorder pipelines face longer development timelines due to higher input costs. however, tariffs are also encouraging localized manufacturing, regional r&d expansion, and strategic sourcing, which may strengthen domestic innovation ecosystems over the long term.

The rna targeting small molecule drug discovery market research report is one of a series of new reports that provides rna targeting small molecule drug discovery market statistics, including rna targeting small molecule drug discovery industry global market size, regional shares, competitors with a rna targeting small molecule drug discovery market share, detailed rna targeting small molecule drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the rna targeting small molecule drug discovery industry. This rna targeting small molecule drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

RNA-targeting small-molecule drug discovery involves the identification and development of small-molecule compounds that bind to RNA molecules to influence their function or activity. This approach supports the development of novel therapies for the treatment of multiple conditions, including genetic disorders, viral infections, neurodegenerative diseases, and cancer.

The main type of RNA-targeting small-molecule drug discovery include messenger RNA (mRNA), non-coding RNA (ncRNA), microRNA (miRNA), and long non-coding RNA (lncRNA). Messenger RNA (mRNA) is an RNA molecule responsible for transferring genetic information from DNA in the cell nucleus to ribosomes, where proteins are synthesized. The technologies used include CRISPR-Cas9, RNA aptamers, small interfering RNA (siRNA), ribozymes, and other approaches applied across several therapeutic areas such as oncology, neurology, infectious diseases, metabolic disorders, genetic conditions, and others. Delivery methods include intravenous (IV), oral, topical, and other routes, and these solutions are utilized for research, therapeutic, diagnostic, and other applications.

The RNA targeting small molecule drug discovery market consists of revenues earned by entities by providing hit identification, hit validation, and hit characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The RNA-targeting small molecule drug discovery market also includes sales of asRNAs and siRNAs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.